Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector Containing Vascular Endothelial Growth Factor cDNA (CI-1023) to Patients with Claudication. - Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector Containing Vascular Endothelial Growth Factor cDNA (CI-1023) to Patients with Claudication.

Description:

The goal of this study was to evaluate the safety and efficacy of CI-1023, an adenovirus encoded with endothelial growth factor isoform 121, in advanced claudication associated with infra-inquinal atherosclerotic vascular disease.